MIR MedMira Inc

HALIFAX, Aug. 13, 2012 /CNW/ - MedMira Inc., (MedMira) , a developer of rapid diagnostic technology and solutions, announced today that it is participating in the Military Health System Research Symposium (MHSRS) taking place August 13-16, 2012 in Fort Lauderdale, FL. During the symposium, MedMira will discuss and demonstrate its unique multiplex rapid diagnostics which are critical tools in the treatment and care of individuals wounded in combat. MHSRS is the premier scientific meeting to address the unique medical needs of the warfighter. The symposium is a collaborative environment for military medical care providers with deployment experience, Department of Defense (DoD) scientists, academia, and industry to facilitate discussions and address the advancement of research and health care development in areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, and Military Infectious Disease Research Programs. "This event provides us with an ideal opportunity to showcase our rapid diagnostics and technology platform and allows us to continue building key relationships with military healthcare personnel within the US Army and other military organizations around the world," said Hermes Chan, CEO, MedMira Inc.  "MHSRS attendees will be keen to see and learn more about our Multiplo Rapid HBV/HIV/HCV Antibody Test, for which we were recently awarded a US Army contract to advance, fully commercialize, and obtain US Food and Drug Administration approval." In July 2012, MedMira was awarded a U.S. Army Medical Research Acquisition Activity (USAMRAA) contract valued at USD$4,266,144 to advance and fully commercialize its multiple rapid test that simultaneously detects three of the most serious infectious diseases, namely HIV-1/2, Hepatitis B, and C antibodies within three minutes using just a small drop of blood. About MedMira MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com. This news release contains forward-looking statements, including statements relating to growth in the Company's business, earnings and profitability, and trends in demand for the Company's products, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. MEDMIRA INC. CONTACT: MedMira Contact:Andrea Young, Corporate CommunicationsTel: 902-450-1588Email: ayoung@medmira.com

Copyright